Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...
In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.
In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering ...
Buffer preparation is one of the most resource-intensive activities in biomanufacturing due to the large number and overall volume of buffers and process liquids used in a typical bioprocess workflow.
Life Science Leader is part of the Life Science Connect network of products and services for life science professionals. Life Science Connect’s vision is to facilitate connections and foster ...
There is no clear metric for measuring a biopharmaceutical organization's energy. However, leaders that direct, create, and conserve energy can enhance employee wellbeing and improve business ...